the third-line rescue therapy with P-CAB for H. pylori infectio
Not Applicable
Recruiting
- Conditions
- Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000029686
- Lead Sponsor
- niversity of Fukui Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
patients with severe liver diseases, patients taking atazanavir sulfate, and so on.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the eradication rate of the third-line rescue therapy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie P-CAB's efficacy in third-line H. pylori eradication?
How does P-CAB compare to standard PPI-based triple therapy in third-line H. pylori treatment outcomes?
Are there specific biomarkers that predict response to P-CAB in H. pylori-infected patients with prior treatment failure?
What are the known adverse events associated with P-CAB use in H. pylori rescue therapy and how are they managed?
What combination therapies or alternative P-CAB formulations are being explored for refractory H. pylori infections?